Nervous Disorder TRIZ Cases

Targeting the eIF2-alpha pathway with specific agents corrects delta-E Torsin1a mis-localization, resolving side effects from symptomatic treatments.

A composite hydrogel supports neuronal regeneration through laminin-guided axonal growth.

PADK and flavonoid compounds boost cathepsin B activity to resolve age-related lysosomal decline and protein accumulation.

Anti-4-HNE monoclonal antibody inhibits cytotoxic oxidative stress substance 4-HNE to achieve targeted anti-inflammatory action.

CXCR4 antagonistic peptides enhance quality of life through non-therapeutic well-being improvement.

An anti-CD40L antibody blocks the CD40 and CD40L interaction to modulate immune responses.

Fenfluramine acts as a 5-HT4 receptor agonist to inhibit seizure-induced respiratory arrest, lowering the risk of sudden unexpected death in epilepsy.

Purified cannabidiol addresses treatment-resistant seizures in Cortical Dysplasia by overcoming conventional drug ineffectiveness.

CAR-modified macrophages clear protein aggregates via phagocytosis, overcoming poor antibody tissue penetration and limited long-term maintenance effects.

N-terminal acetylation and C-terminal amidation extend peptide plasma half-life, enabling lower therapeutic dosages for diabetes treatment.

Nitrite salts of 1,1-dimethylbiguanide improve therapy effectiveness by reducing morbidity and mortality from cardiovascular diseases.

Nepenthes enzymes degrade proline-rich gluten peptides to eliminate immune triggers and inflammation.

Antisense oligonucleotides target the natural antisense transcript of apolipoprotein-A1 to modulate expression.

Umbilical cord mesenchymal stem cells reduce brain injury and weight loss in inflammatory disease models.

Pairing phenethyl isothiocyanate with abiraterone or enzalutamide enhances therapeutic efficacy while reducing toxicity to normal cells.

Enterococcus and Bacteroides probiotic compositions modulate the gut-brain axis to improve communication behaviors in neurodevelopmental disorders.

Antigen binding proteins target LAG-3 to deplete activated T cells, resolving specificity risks in autoimmune and cancer therapies.

Analgecine decreases lactic acid levels and increases superoxide dismutase activity to mitigate ischemic injury side effects.

Combination medication uses meclizine to treat migraine nausea and histamine triggers alongside acetaminophen pain relief.

Controlled VEGF elevation reduces muscle wasting and steatosis while extending lifespan.

Merges alpha-2 adrenergic agonist therapy with inositol to resolve insufficient symptom coverage while maintaining treatment simplicity.

Replication-defective HSV vectors eliminate cellular cytotoxicity while maintaining robust transgene expression through extracted immediate-early genes.

A small molecule compound activates TFEB to enhance autophagy and lysosome biogenesis for clearing toxic protein aggregates.

Granulocyte colony-stimulating factor reduces menopausal symptoms and arthritis pain through immune modulation.

Heterocyclic purine derivatives activate the Nrf2 antioxidant response element to increase neuronal viability.

Plasma protein fraction eliminates opioid addiction risks while accelerating surgical recovery via multi-functional biological mechanisms.

PEGylation of amyloid beta binding Fab fragments extends half-life without antigen-antibody complex accumulation.

Anti-BTLA antibodies block the BTLA-HVEM interaction to treat cancers unresponsive to CTLA-4 or PD-1/PD-L1 therapies.

Granulocyte colony stimulating factor agent increases nerve conduction velocity and improves pain sensitivity by regenerating peripheral blood vessels.

Mesenchymal stem cells expand regulatory T-cells through antigen-specific co-culture.

Attenuated bacteria expressing multi-species prion peptides provide universal protection against prion diseases across diverse mammalian species.

Lactobacillus plantarum PS128 synthesizes dopamine and serotonin in the gut to address variable efficacy of conventional AADC treatments.

Alpha-NETA analogs block chemerin-driven CMKLR1 signaling to reduce MS severity without compromising systemic immunity.

Modified nucleosides and local functionalization resolve chemical stability and immune response trade-offs in targeted delivery.

A lyophilized lipid cake hydrates with a pH-controlled buffer to form a sustained-release anesthetic complex.

Targeted PIKfyve kinase inhibitors reduce inflammatory responses by selectively modulating IL-12 and IL-23, avoiding broad immunosuppression.

Ex vivo prognostic assays assess apoptosis and CD40 signaling biomarkers to determine patient responsiveness to anti-CD40 therapeutic agents.